BACKGROUND: Because of a high cardiovascular disease (CVD) risk in people with Familial Hypercholesterolemia (FH), early prevention of cardiovascular disease is important for health gain and cost reduction. This project focuses on the development and evaluation of an innovative intervention aiming to reduce CVD risk by promoting a healthy lifestyle among people with FH. METHODS: This project is designed as a randomised controlled trial in which individuals with FH will be assigned randomly to a control or intervention group. In the intervention group (n = 200), participants will receive a personalized intervention which is a combination of web-based tailored lifestyle advice and personal counselling by a lifestyle coach. The control group (n = 200) will receive care as usual. Primary outcomes are biological indicators of CVD risk: systolic blood pressure, glucose, BMI, waist circumference and lipids (triglycerides, total, LDL and HDL cholesterol). Secondary outcomes are: healthy lifestyle behaviour (with regard to smoking, physical activity, dietary pattern and compliance to statin therapy) and psychological correlates and determinants of healthy lifestyle behaviour (knowledge, attitude, risk perception, social influence, self-efficacy, cues to action, intention and autonomy). Measurement will take place at baseline, and at 3 and 12 months after randomisation. Additionally, a throughout process-evaluation will be conducted to assess and monitor intervention implementation during the trial. DISCUSSION: Results of the PRO-FIT project will provide information about the effects and implementation of a healthy lifestyle intervention for individuals with FH. Our experiences with this intervention will be indicative about the suitability, feasibility and benefits of this approach for future interventions in other high-risk groups, such as Familial Combined Hypercholesterolemia (FCH) and diabetes. TRIAL REGISTRATION NUMBER: NTR1899.
RCT Entities:
BACKGROUND: Because of a high cardiovascular disease (CVD) risk in people with Familial Hypercholesterolemia (FH), early prevention of cardiovascular disease is important for health gain and cost reduction. This project focuses on the development and evaluation of an innovative intervention aiming to reduce CVD risk by promoting a healthy lifestyle among people with FH. METHODS: This project is designed as a randomised controlled trial in which individuals with FH will be assigned randomly to a control or intervention group. In the intervention group (n = 200), participants will receive a personalized intervention which is a combination of web-based tailored lifestyle advice and personal counselling by a lifestyle coach. The control group (n = 200) will receive care as usual. Primary outcomes are biological indicators of CVD risk: systolic blood pressure, glucose, BMI, waist circumference and lipids (triglycerides, total, LDL and HDL cholesterol). Secondary outcomes are: healthy lifestyle behaviour (with regard to smoking, physical activity, dietary pattern and compliance to statin therapy) and psychological correlates and determinants of healthy lifestyle behaviour (knowledge, attitude, risk perception, social influence, self-efficacy, cues to action, intention and autonomy). Measurement will take place at baseline, and at 3 and 12 months after randomisation. Additionally, a throughout process-evaluation will be conducted to assess and monitor intervention implementation during the trial. DISCUSSION: Results of the PRO-FIT project will provide information about the effects and implementation of a healthy lifestyle intervention for individuals with FH. Our experiences with this intervention will be indicative about the suitability, feasibility and benefits of this approach for future interventions in other high-risk groups, such as Familial Combined Hypercholesterolemia (FCH) and diabetes. TRIAL REGISTRATION NUMBER: NTR1899.
Authors: Ken Resnicow; Alice Jackson; Ronald Braithwaite; Colleen DiIorio; Dhana Blisset; Simone Rahotep; Santhi Periasamy Journal: Health Educ Res Date: 2002-10
Authors: Nathan Hutting; Sarah I Detaille; Yvonne F Heerkens; Josephine A Engels; J Bart Staal; Maria W G Nijhuis-van der Sanden Journal: J Occup Rehabil Date: 2017-03
Authors: F J Kinnear; E Wainwright; J E Bourne; F E Lithander; J Hamilton-Shield; A Searle Journal: BMC Health Serv Res Date: 2020-01-08 Impact factor: 2.655
Authors: Karen Broekhuizen; Judith G M Jelsma; Mireille N M van Poppel; Lando L J Koppes; Johannes Brug; Willem van Mechelen Journal: BMC Public Health Date: 2012-05-14 Impact factor: 3.295
Authors: Karen Broekhuizen; Mireille N M van Poppel; Lando L Koppes; Iris Kindt; Johannes Brug; Willem van Mechelen Journal: PLoS One Date: 2012-12-12 Impact factor: 3.240
Authors: Karen Broekhuizen; Marieke F van Wier; Lando L J Koppes; Johannes Brug; Willem van Mechelen; Judith E Bosmans; Mireille N M van Poppel Journal: BMC Res Notes Date: 2015-07-29